Intellia Therapeutics reports serious liver enzyme elevation in one patient during Phase 3 trial of nex-z gene editing therapy for ATTR cardiomyopathy; shares drop 26% ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone therapy, comparable to Menarini's Orserdu.

Unit­ed­Health Group’s Op­tum is shut­ting down its vir­tu­al care busi­ness, End­points News has learned. Known as Op­tum Vir­tu­al Care, the busi­ness pro­vides on­line ur­gent ...

No­vo Nordisk spelled out how it will try to catch up with the ex­tra­or­di­nary de­mand for its GLP-1 drugs, un­der­scor­ing its ra­tio­nale for its in … ...

Sarep­ta and Roche’s con­fir­ma­to­ry study for a Duchenne gene ther­a­py failed to hit its pri­ma­ry end­point, com­pli­cat­ing plans to con­vert the drug’s la­bel in­to a … ...

Eli Lil­ly will pay up to $1.925 bil­lion in cash for weight loss drug­mak­er Ver­sa­nis, mark­ing the Big Phar­ma’s fourth ac­qui­si­tion this sum­mer af­ter deals … ...

Ver­tex sued the fed­er­al gov­ern­ment on Mon­day in an ef­fort to ex­pand its fer­til­i­ty sup­port pro­gram to cer­tain pa­tients tak­ing its new gene ther­a­py for … ...

French biotech Smart Im­mune has raised more than half of its rough­ly €50 mil­lion ($54 mil­lion) tar­get in an on­go­ing Se­ries A round, with an … ...

BioAge Labs has reeled in the biotech in­dus­try’s largest pri­vate fi­nanc­ing round so far in 2024 as the Cal­i­for­nia start­up goes full throt­tle on the … ...

Gene ther­a­py start­up en­Gene be­came a pub­lic biotech on Wednes­day af­ter com­plet­ing its com­bi­na­tion with For­bion Eu­ro­pean Ac­qui­si­tion, a blank check com­pa­ny ...

When End­points News launched our Health Tech newslet­ter in Fall 2023, it was the first time our news­room had stepped out­side the world of bio­phar­ma … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.